Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC)

• Published in: European journal of surgical oncology Vol. 50; no. 2; p. 107954
• Main Authors: Rocco, Nicola, Ghilli, Matteo, Curcio, Annalisa, Bortul, Marina, Burlizzi, Stefano, Cabula, Carlo, Cabula, Roberta, Ferrari, Alberta, Folli, Secondo, Fortunato, Lucio, Frittelli, Patrizia, Gentilini, Oreste, Grendele, Sara, Grassi, Massimo Maria, Grossi, Simona, Magnoni, Francesca, Murgo, Roberto, Palli, Dante, Rovera, Francesca, Sanguinetti, Alessandro, Taffurelli, Mario, Tazzioli, Giovanni, Terribile, Daniela Andreina, Caruso, Francesco, Galimberti, Viviana
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-02-2024
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2024.107954

De-escalation of axillary surgery in breast cancer (BC) management began when sentinel lymph node biopsy (SLNB) replaced axillary lymph node dissection (ALND) as standard of care in patients with node-negative BC. The second step consolidated ALND omission in selected subgroups of BC patients with up to two macrometastases and recognized BC molecular and genomic implication in predicting prognosis and planning adjuvant treatment.
Outcomes from the recent RxPONDER and monarchE trials have come to challenge the previous cut-off of two SLN in order to inform decisions on systemic therapies for hormone receptor-positive (HR+), human epidermal growth factor receptor type-2 (HER2) negative BC, as the criteria included a cut-off of respectively three and four SLNs.
In view of the controversy that this may lift in surgical practice, the Italian National Association of Breast Surgeons (Associazione Nazionale Italiana Senologi Chirurghi, ANISC) reviewed data regarding the latest trials on this topic and proposes an implementation in clinical practice.
We reviewed the available literature offering data on the pathological nodal status of cN0 breast cancer patients.
The rates of pN2 status in cN0 patients ranges from 3.5 % to 16 %; pre-surgical diagnostic definition of axillary lymph node status in cN0 patients by ultrasound could be useful to inform about a possible involvement of ≥4 lymph nodes in this specific sub-groups of women.
The Italian National Association of Breast Surgeons (ANISC) considers that for HR + HER2-/cN0-pN1(sn) BC patients undergoing breast conserving treatment the preoperative workup should be optimized for a more detailed assessment of the axilla and the technique of SLNB should be optimized, if considered appropriate by the surgeon, not considering routine ALND always indicated to determine treatment recommendations according to criteria of eligibility to RxPONDER and monarch-E trials.